Pneumococcal biliary tract infections – How rare are they?

Morioka, Hiroshi; Iguchi, Mitsutaka; Oodate, Mitsuru; Yoneda, Masaki; Ushijima, Futoshi; Hirabayashi, Aki; Tetsuka, Nobuyuki; Tomita, Yoshihiko; Kato, Daizo; Yagi, Tetsuya

doi:10.1016/j.jiac.2016.11.008

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pneumococcal disease is causing some kinds of infections such as pneumonia, meningitis, bacteremia, infective endocarditis, etc. [9][10][11][12]93]. Pneumococcal disease is one of the most common VPD, causing a life-threatening in people of all ages.…”

Section: Discussionmentioning

confidence: 99%

“…IPD, such as meningitis, bacteremia, and sepsis, is the most severe presentation and shows high mortality, despite the advancement of antimicrobial treatment. Septic arthritis [9], biliary tract infection [10], infective endocarditis [11], and mycotic aortic aneurysm [12] due to this pathogen have been reported, which sporadically happens. The pneumococcal vaccine is one of the most valuable methods for the prevention of pneumococcal disease.…”

Section: Epidemiology and Economic Burdenmentioning

confidence: 99%

See 1 more Smart Citation

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Asai

Mikamo

2021

Microorganisms

View full text Add to dashboard Cite

Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19–64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician’s point of view.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Epidemiology and Economic Burdenmentioning

confidence: 99%